용인세브란스병원은 1983년에 개원한 연세대학교 의과대학 병원이자 대한민국의 종합병원이다.

During the past decade, Yongin Severance Hospital conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 2 clinical trials were completed, i.e. on average, 11.1% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yongin Severance Hospital" #1 sponsor was "Yonsei University" with 7 trials, followed by "Gangnam Severance Hospital" with 3 trials sponsored, "National Cancer Institute (NCI)" with 2 trials sponsored, "Pharmicell Co., Ltd." with 2 trials sponsored and "GNT Pharma" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yongin Severance Hospital" #1 collaborator was "Severance Hospital" with 4 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator, "CardioVascular Research Foundation, Korea" with 1 trials as a collaborator and "Genoss Co., Ltd." with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Yongin Severance Hospital" are "Coronary Artery Disease" (4 trials), "Alcoholic Cirrhosis" (2 trials), "Fallopian Tube Endometrioid Adenocarcinoma" (2 trials), "Fallopian Tube Mucinous Adenocarcinoma" (2 trials) and "Fallopian Tube Transitional Cell Carcinoma" (2 trials). Many other conditions were trialed in "Yongin Severance Hospital" in a lesser frequency.

Most popular intervention types in "Yongin Severance Hospital" are "Drug" (9 trials), "Biological" (4 trials), "Other" (4 trials), "Procedure" (4 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Paclitaxel" (3 trials), "Bevacizumab" (2 trials), "Cellgram-LC" (2 trials) and "Laboratory Biomarker Analysis" (2 trials). Other intervention names were less common.

The vast majority of trials in "Yongin Severance Hospital" are 18 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Yongin Severance Hospital". undefined are not yet recruiting, 11 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Yongin Severance Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Yongin Severance Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".